Cellular Origins Secures $40M Series A To Scale Cell Therapy Manufacturing

The round was led by Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., with participation from Highland Europe, BGF, NYBC Ventures, and TTP Group.

The company plans to use the funds to expand its commercial team, broaden the range of unit operations integrated into its platform, and build the systems and infrastructure necessary for full manufacturing and service scale-up.

Led by CEO Edwin Stone, Cellular Origins is enabling the manufacturing of cell therapies at scale through a factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem combines mobile robotics and automated sterile welding with proven bioprocess instruments.

Read Also - Dutch Beverage Startup Founteyn Secures €19.3M In Series A Round

The platform is already used by market leaders such as Cytiva, Fresenius Kabi, Thermo Fisher Scientific, and Wilson Wolf.

Looking ahead, the company aims to extend its capabilities beyond cell therapies and into the wider Advanced Therapies Medicinal Products (ATMP) sector.

“This fundraise is a pivotal milestone in our mission to industrialise cell therapy manufacturing ” said Edwin Stone CEO, Cellular Origins. “The support from our investors is a strong endorsement of both our technology and the urgent need for scalable automated solutions in this space. It recognises the progress that Cellular Origins, its partners and customers have collectively made towards enabling access to cell therapies at scale.

This investment gives us access to the capital and networks to drive our next phase of growth. Through this fundraise we will accelerate the development and deployment of our robotic platform to help make life-saving cell therapies more accessible, reliable, and affordable.”

About Cellular Origins

Cellular Origins enables large-scale cell therapy manufacturing through its Constellation platform, combining mobile robotics, automated sterile welding, and bioprocess instruments. Trusted by industry leaders, it provides flexible, future-proof automation, supporting efficient, reliable production from clinical trials to commercial scale while accelerating ATMP growth.